Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1771 to 1785 of 8234 results

  1. Retatrutide for managing overweight and obesity [ID6644]

    Awaiting development Reference number: GID-TA11845 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Digital flexor tenotomy for diabetic foot

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date:  18 March 2026

    Technology appraisal guidance
    In development

  4. Dermal allograft augmentation in proximal humerus fracture fixation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]

    Awaiting development Reference number: GID-TA11744 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    Awaiting development Reference number: GID-TA11743 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]

    Awaiting development Reference number: GID-TA11667 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    In development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ruxolitinib for Prurigo Nodularis [ID6571]

    In development Reference number: GID-TA11760 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]

    Awaiting development Reference number: GID-TA11720 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Elinzanetant for Vasomotor symptoms [ID6544]

    Awaiting development Reference number: GID-TA11784 Expected publication date:  21 July 2027

    Technology appraisal guidance
    Awaiting development

  13. Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]

    Awaiting development Reference number: GID-TA11721 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    Awaiting development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [TSID9130]

    Awaiting development Reference number: GID-TA11325 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development